Navigation Links
Neurocrine Biosciences Reports First Quarter 2012 Results
Date:5/2/2012

hich began in June 2010. During the first quarter of 2012, the Company recognized revenue of $2.0 million in the form of sponsored development funding under these two agreements compared to $3.2 million of sponsored development revenue during the first quarter of 2011.

Research and development expenses increased to $9.4 million during the first quarter of 2012 compared with $7.3 million for the same period in 2011.  The increase in expense was a result of higher external clinical development expenses related to the VMAT2 program, partially offset by lower external clinical development expenses related to the elagolix program. The Company also incurred costs during the first quarter of 2012 related to early stage programs for external testing and scientific consulting that accounted for $0.7 million of the increase. Additionally, research and development personnel expenses were higher quarter over quarter, primarily due to a $0.3 million increase in share-based compensation expense. General and administrative expenses increased from $3.2 million in the first quarter of 2011 to $3.7 million for the first quarter of 2012. This increase is primarily driven by higher share-based compensation expense which increased by $0.4 million.

Pipeline HighlightsElagolix Update
During April 2012, Abbott held the investigator meeting to launch the Phase III program for elagolix in endometriosis. The screening of patients for the Phase III clinical program of elagolix for endometriosis is expected to commence in the second quarter of 2012.

Abbott continues to enroll subjects in a large Phase II study of elagolix in uterine fibroids. This study will assess uterine blood loss in 325 women with heavy uterine bleeding due to uterine fibroids.

VMAT2 Update
The Company's VMAT2 inhibitor, NBI-98854, recently completed a second Phase II study assessing the efficacy of NBI-98854 in tardive dyskinesia patients. The design of th
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
(Date:5/29/2015)... 29, 2015 Educating the community continues ... for the Advancement of Wound Care (AAWC), which ... from AAWC,s corporate partners, the Association provides medical ... the AAWC website at http://aawconline.org/education-for-the-generalist/ . The ... with links to various CME/CEU educational programs. This ...
(Date:5/28/2015)... 28, 2015 Research ... addition of Jain PharmaBiotech,s new report  "RNAi ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... silencing involves the use of double stranded ... material is processed into short 21-23 nucleotide ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... ... that a new market research report is available in ... Trends , http://www.reportlinker.com/p0164367/Immunoassay-Instruments---Global-Market-Trends.html , Immunoassay ... years due to the innovation of new technologies and ...
... ... a new market research report is available in its ... Market Analysis , http://www.reportlinker.com/p0164335/Cardiac-Pacemakers---A-World-Market-Analysis.html , ... expanding cardiovascular devices market. The worldwide cardiac pacemakers market ...
Cached Medicine Technology:Reportlinker Adds Immunoassay Instruments - Global Market Trends 2Reportlinker Adds Immunoassay Instruments - Global Market Trends 3Reportlinker Adds Immunoassay Instruments - Global Market Trends 4Reportlinker Adds Immunoassay Instruments - Global Market Trends 5Reportlinker Adds Immunoassay Instruments - Global Market Trends 6Reportlinker Adds Immunoassay Instruments - Global Market Trends 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10
(Date:5/29/2015)... “In the current environment of opiate ... we provide education that will help practitioners address ... from pain, within the boundaries of the guidelines ... rehabilitation medicine and President/Medical Director of the International ... A new flight of PAINWeekEnd Regional Conferences offers ...
(Date:5/29/2015)... Tallahassee, FL (PRWEB) May 29, 2015 Ready ... trip, it’s important for all drivers to get their vehicles ... do to be prepared. Advanced Driving Systems (ADS) is ready ... some tips on preparing for summer road trips. , When ... do the following to ensure that the trip goes smoothly ...
(Date:5/29/2015)... May 29, 2015 The science of ... Los Angeles thanks to the efforts of internationally recognized ... has combined ARTAS hair restoration and manual ... restoration procedures available anywhere. , A Follicular Unit ... individually harvesting hair follicle grafts from the donor areas ...
(Date:5/29/2015)... Rhode Island (PRWEB) May 29, 2015 ... 7, 2015. The event, now closed to new registration, ... Fort Adams. This exciting competitive running event demonstrates ... organizations to create a public benefit – in this ... scenic coastal views around the famed Ocean Drive and ...
(Date:5/29/2015)... Abington Hospital – Jefferson Health has ... in the nation to join the EMPower ... work toward achieving the Baby-Friendly USA© designation. , ... maternity care practices leading to Baby-Friendly designation. Funded ... EMPower is aimed at increasing breastfeeding rates throughout ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:Los Angeles and Beverly Hills Hair Transplant Doctor Now Combines Robotic Hair Restoration (ARTAS) and Manual FUE Transplants for Maximum Hair Coverage 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Abington Hospital Selected to Join Baby-Friendly Hospital Initiative 2
... BEACH, Va., May 30 AMERIGROUP,Corporation (NYSE: AGP ... Sachs Global Healthcare Conference on June 11 at Dana ... which begins Wednesday,June 11 at 5:40 p.m. Eastern Time, ... on the investors, page. A replay of,the webcast will ...
... smoked cigarettes or used other tobacco products for many ... cancer will return, according to research by Dana-Farber Cancer ... of the American Society of Clinical Oncology (ASCO), May ... 965 patients treated for stage III colon cancer, investigators ...
... were more likely than whites to die in a ... blacks for life-extending treatment even in the face of ... researchers at Dana-Farber Cancer Institute in Boston. ,The findings ... of the American Society of Clinical Oncology in Chicago ...
... more than 2,000 years ago by Hippocrates, has finally been ... The phenomenon of "finger clubbing", a deformity of the fingers ... has long been recognized to be a sign of a ... "It,s one of the first things they teach you at ...
... at the American College of Sports Medicine Annual ... zero-calorie, zero sweetener water beverage, developed by researchers ... hydrates as well as a leading sports/electrolyte drink, ... calories, and artificial ingredients many sports beverages offer ...
... rich in fruits and vegetables and low in animal ... to the so-called Mediterranean diet, which is rich in ... protect you against developing type 2 diabetes, a Spanish ... as a way to guard against cardiovascular disease, but ...
Cached Medicine News:Health News:Black patients with terminal cancer more likely to choose aggressive care at end of life 2Health News:Leeds medics solve an ancient riddle -- and offer new tool for diagnosis 2Health News:Zero-calorie Aqua-Lyte hydrates as well as leading sports drink 2Health News:Mediterranean Diet May Ward Off Type 2 Diabetes 2Health News:Mediterranean Diet May Ward Off Type 2 Diabetes 3
... providing excellence in Ambulatory ECG Monitoring ... physicians in the diagnosis and treatment ... each year. State-of-the-art equipment and technology ... highest standard of customer service makes ...
... is an e-health service developed by ... Telemedicine patient monitoring devices. Designed ... monitoring devices, AerotelNet.com improves patient and ... advanced communication capabilities make it easy ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Medicine Products: